PUMA Mediates the Apoptotic Response to p53
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
cancer (p53 pathway apoptosis)
Modality
Gene Therapy
Mechanism
PUMA / p53 apoptosis pathway activator
Target
TP53
rNPV Envelope
Low
-$15.8M
costs +25% · peak −25%
Base
-$12.5M
cumulative PoS 0.4%
High
-$9.3M
costs −25% · peak +25%
This is an illustrative p53-pathway gene-therapy envelope only because the pipeline requires stages. The actual asset is a basic-science PUMA/p53 apoptosis finding; PoS is therefore materially lower than a defined adenoviral p53 product.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.50
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.572 — composite-score rank #41 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#7) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
PUMA / BBC3 p53-apoptosis discovery
The direct asset: PUMA as a p53-induced mediator of apoptosis. It is a mechanistic finding in cancer biology, not a gene-therapy candidate.
Criteria 1: exact mechanism; not a drug comparator.
Gendicine / rAd-p53
Closest p53-pathway gene-therapy archetype: an adenoviral p53 product approved in China for head and neck cancer. It anchors what an actual p53 gene-therapy product would look like, but it is not PUMA.
Criteria 3 and 4: p53-pathway regulatory archetype; not same target/product.
p53-based cancer therapy literature
Adjacent therapeutic context showing that p53 pathway restoration can be productized only when a defined vector/drug exists.
Criteria 1 and 4: same pathway, different product reality.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $5.0M | 18 mo | 22.0% | [0] [1] |
| Phase I | $22.0M | 18 mo | 46.0% | [1] [2] |
| Phase II | $70.0M | 30 mo | 17.0% | [1] [2] |
| Phase III | $170.0M | 42 mo | 32.0% | [2] [3] |
| NDA/BLA Review | $12.0M | 12 mo | 80.0% | [2] |
Multiplier handling: No multipliers eligible for this asset under the locked methodology. See methodology for the rule.
Peak revenue and discount rate
$50.0M peak · WACC 16.0%
Peak revenue. The current asset has no drug substance or proprietary product peak. The $50M illustrative figure reflects possible grant, reagent, or follow-on licensing value if separately productized, not a cancer-therapy revenue forecast.
WACC. Basic cancer-biology discovery without a defined therapeutic modality has very high translation risk and low standalone commercial relevance.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$12.5M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$63.3M
P25
-$10.7M
P50 (median)
-$4.7M
P75
-$3.1M
P95
-$1.7M
Prob ≥ 0
0.0%
Evidence register
4 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is PUMA/p53 pathway biology cmo_findings.asset_class_reality | PUMA Mediates the Apoptotic Response to p53 regulatory | 2014-10-07 | high |
Original PUMA discovery comparators[0] | PUMA, a Novel Proapoptotic Gene, Is Induced by p53 peer_review | 2001-03-01 | high |
p53 gene therapy product archetype comparators[1] | The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic peer_review | 2018-01-01 | high |
Clinical p53 pathway context stage_profile.phase_3.pos | Expert consensus on recombinant adenovirus human p53 for head and neck cancers peer_review | 2021-09-24 | medium |
Thesis
Why this asset earns its rank
This is a basic-science finding, not a therapeutic asset. The invention points to PUMA/BBC3 as a mediator of p53-dependent apoptosis in cancer cells; that matters scientifically, but it is not a vector, molecule, antibody, or drug candidate. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified grant_non_commercial.
The closest product comparator is not PUMA; it is Gendicine, an adenoviral p53 gene-therapy product approved in China. That comparator shows what a real p53-pathway therapy looks like only after the biology is embedded in a specific vector and indication. The engine result is -$15.8M to -$9.3M, with a base rNPV of -$12.5M and cumulative PoS of 0.4%; that placeholder should not be read as PUMA-product value because no such product exists in the asset file.
Verdict: important biology, non-commercial at this stage. It earns its rank because the p53 pathway is clinically central and the gene_therapy bucket is powerful in the rubric, but a CMO would reject any manufactured PUMA drug DCF.
Key risks
Asset-specific, not generic biotech risks
- Asset-class mismatch: PUMA mediating p53 apoptosis is a discovery, not a product candidate.
- No modality: the asset file does not specify gene delivery, peptide mimicry, small molecule, or any drug-like intervention.
- P53-pathway complexity: tumors frequently disable p53 upstream or downstream, so simply invoking PUMA does not define a therapeutic window.
- Commercial moat risk: follow-on productization would need new IP around an actual modality, not just the historic pathway finding.